Fig. 1
From: EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
Roles of EZH2 in multiple myeloma. EZH2 can act as a pro-oncogene, through transcriptional silencing of tumor suppressors (TS) or indirect upregulation of oncogenes. EZH2 can also act as a tumor suppressor by inactivating the phosphorylation by cell adhesion-mediated drug resistance (CAM-DR) mechanisms, leading to sustained expression of anti-apoptotic genes. EZH2 is also involved in the maintenance of multiple myeloma stem cell-like side populations (MM-SCSs)